Latest news
6 ways Johnson & Johnson is using AI to help advance healthcare
Artificial intelligence is revolutionizing healthcare—from improving surgical training and procedures to equipping healthcare providers with insights and personalizing care for patients around the world. See how the company is harnessing its extraordinary power.
More from Johnson & Johnson
What you need to know about Johnson & Johnson’s 2024 third quarter earnings
Check out this infographic breakdown of the company’s third quarter performance, with highlights from its Innovative Medicine and MedTech businesses.
What is a rheumatic disease?
More than 200 conditions are classified as rheumatic diseases, including rheumatoid arthritis, lupus and Sjögren’s disease. They tend to affect the joints and connective tissues, causing pain and swelling and impacting quality of life. Here’s what a doctor wants you to know about the different types, symptoms and risk factors—and how Johnson & Johnson is innovating new treatments.
Meet the medical engineer behind the innovative heart pump that revolutionized cardiac health
Drawing on his fascination with airplane technology, Thorsten Siess, Ph.D., came up with an idea that became the Impella heart pump. Now, 25 years since it entered the market, this groundbreaking device has helped more than 330,000 patients recover from heart injuries.
What’s the difference between a heart attack and cardiac arrest?
Both are life-threatening heart-health emergencies, but they are two distinct conditions with different causes and treatment. Here’s what a cardiologist wants you to know.
What you need to know about Johnson & Johnson’s 2023 transparency report
The annual report has just been released—here are key takeaways that showcase the company’s commitment to creating a more sustainable, equitable and innovative healthcare system.
How Johnson & Johnson is fighting counterfeit medical products
Fake medication and compromised devices are part of a global market that poses a significant threat to the health of patients. Here’s how the company’s Global Brand Protection team helps keep people safe.
Photo courtesy of GBP LATAM team
Press releases
Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results
Icotrokinra (JNJ-2113), a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor, met its co-primary endpoints in patients with moderate to severe plaque psoriasis 74% of patients achieved clear or almost clear skin (IGA 0/1) at week 24 Comprehensive results are being prepared for presentation at upcoming medical congresses
CHMP recommends RYBREVANT®▼ (amivantamab) in combination with LAZCLUZE®▼ (lazertinib) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer
The amivantamab plus lazertinib combination regimen offers potential to provide new standard of care as first-line option for adult patients with advanced NSCLC with EGFR ex19del or L858R substitution mutations1 In the Phase 3 MARIPOSA study, amivantamab plus lazertinib significantly reduced risk of disease progression or death by 30 percent versus osimertinib monotherapy1
Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren’s disease study
Adults with moderately-to-severely active Sjögren’s disease who received investigational FcRn blocker nipocalimab had improvements in disease activity scores at 24 weeks with accompanying significant reductions in IgG and autoantibody levels Nipocalimab was granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren’s disease based on results from the Phase 2 DAHLIAS study
Johnson & Johnson MedTech Announces Strategic Agreement with Responsive Arthroscopy to Expand Sports Soft Tissue Solutions
New collaboration to strengthen and deliver advanced soft tissue repair solutions for shoulder, foot and ankle procedures
Johnson & Johnson MedTech Receives IDE Approval for OTTAVA™ Robotic Surgical System
Company prepares to support clinical trial in the United States
